Login to Your Account

Ampio shares climb as final pivotal data pave path to FDA filing

By Michael Fitzhugh
Staff Writer

Thursday, December 14, 2017

New pivotal phase III results positioning the nonsteroidal anti-inflammatory Ampion for potential approval in severe osteoarthritis of the knee pushed shares of its developer, Ampio Pharmaceuticals Inc., to touch a 52-week high on Thursday before pulling back somewhat.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription